Transderm Scop
Nausea, Anesthetic premedication therapy, Airsickness + 2 more
Treatment
5 Active Studies for Transderm Scop
Treatment for
Nausea
What is Transderm Scop
Scopolamine
The Generic name of this drug
Treatment Summary
Scopolamine is a medication used to block the activity of acetylcholine, a neurotransmitter in the body. It is derived from plants in the Solanaceae family and was first synthesized in 1959. Scopolamine is most commonly used to prevent nausea and vomiting caused by motion sickness or surgery. It was first approved by the FDA in 1979 and is available as both tablets and a patch.
Belladonna Alkaloids with Phenobarbital
is the brand name
Transderm Scop Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Belladonna Alkaloids with Phenobarbital
Scopolamine
1966
13
Effectiveness
How Transderm Scop Affects Patients
Scopolamine is a medication that works by blocking the nerve pathways that control the body's sweat and saliva production. It is usually applied as a patch that works over three days and can still be detected in urine up to 108 hours later. Using scopolamine may increase eye pressure, so it should be used with caution in those with glaucoma. It can also cause mental side effects, like confusion, seizures, and changes in behavior. Women with preeclampsia should avoid using this drug. People with stomach or urinary problems should be monitored and scopolamine should be stopped if these problems get worse. Blurred vision can
How Transderm Scop works in the body
Acetylcholine is a neurotransmitter that helps regulate the body through five different types of receptors. Scopolamine is an anticholinergic drug which blocks these receptors, leading to therapeutic and adverse effects. It is used to treat nausea and vomiting by altering signaling in the central nervous system. Scopolamine may also be useful in treating mental health disorders like schizophrenia and substance abuse.
When to interrupt dosage
The amount of Transderm Scop is contingent upon the diagnosed ailment, including Preanesthetic Medication, Nausea and Motion Sickness. The measure of dosage is dependent on the delivery approach (e.g. Oral or Elixir) specified in the table below.
Condition
Dosage
Administration
Motion Sickness
, 0.1 mg/hour, 0.0065 mg/mL, 0.0065 mg, 0.4 mg/mL, 0.0195 mg, 0.025 mg/mg, 0.05 mg/mg, 0.4 mg, 0.0033 mg, 1.0 mg, 3.0 mg/mL, 2.5 mg/mL, 0.006 mg/mL, 1.5 mg, 0.6 mg/mL, 0.00065 mg/mL
, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Liquid - Oral, Solution - Ophthalmic, Ophthalmic, Tablet, soluble, Tablet, soluble - Oral, Topical, Patch, extended release - Topical, Patch, Patch - Transdermal
Anesthetic premedication therapy
, 0.1 mg/hour, 0.0065 mg/mL, 0.0065 mg, 0.4 mg/mL, 0.0195 mg, 0.025 mg/mg, 0.05 mg/mg, 0.4 mg, 0.0033 mg, 1.0 mg, 3.0 mg/mL, 2.5 mg/mL, 0.006 mg/mL, 1.5 mg, 0.6 mg/mL, 0.00065 mg/mL
, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Liquid - Oral, Solution - Ophthalmic, Ophthalmic, Tablet, soluble, Tablet, soluble - Oral, Topical, Patch, extended release - Topical, Patch, Patch - Transdermal
Airsickness
, 0.1 mg/hour, 0.0065 mg/mL, 0.0065 mg, 0.4 mg/mL, 0.0195 mg, 0.025 mg/mg, 0.05 mg/mg, 0.4 mg, 0.0033 mg, 1.0 mg, 3.0 mg/mL, 2.5 mg/mL, 0.006 mg/mL, 1.5 mg, 0.6 mg/mL, 0.00065 mg/mL
, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Liquid - Oral, Solution - Ophthalmic, Ophthalmic, Tablet, soluble, Tablet, soluble - Oral, Topical, Patch, extended release - Topical, Patch, Patch - Transdermal
Nausea
, 0.1 mg/hour, 0.0065 mg/mL, 0.0065 mg, 0.4 mg/mL, 0.0195 mg, 0.025 mg/mg, 0.05 mg/mg, 0.4 mg, 0.0033 mg, 1.0 mg, 3.0 mg/mL, 2.5 mg/mL, 0.006 mg/mL, 1.5 mg, 0.6 mg/mL, 0.00065 mg/mL
, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Liquid - Oral, Solution - Ophthalmic, Ophthalmic, Tablet, soluble, Tablet, soluble - Oral, Topical, Patch, extended release - Topical, Patch, Patch - Transdermal
Nausea
, 0.1 mg/hour, 0.0065 mg/mL, 0.0065 mg, 0.4 mg/mL, 0.0195 mg, 0.025 mg/mg, 0.05 mg/mg, 0.4 mg, 0.0033 mg, 1.0 mg, 3.0 mg/mL, 2.5 mg/mL, 0.006 mg/mL, 1.5 mg, 0.6 mg/mL, 0.00065 mg/mL
, Transdermal, Patch, extended release, Patch, extended release - Transdermal, Oral, Elixir, Elixir - Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Solution, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Liquid - Oral, Solution - Ophthalmic, Ophthalmic, Tablet, soluble, Tablet, soluble - Oral, Topical, Patch, extended release - Topical, Patch, Patch - Transdermal
Warnings
Transderm Scop Contraindications
Condition
Risk Level
Notes
Uropathy Obstructive
Do Not Combine
Arterial Occlusive Diseases
Do Not Combine
Myasthenia Gravis
Do Not Combine
Ulcerative Colitis
Do Not Combine
Cardiovascular Physiological Phenomena
Do Not Combine
Ulcerative Colitis
Do Not Combine
Uterine Inertia
Do Not Combine
Pulse Frequency
Do Not Combine
Intestinal Pseudo-Obstruction
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Scopolamine may interact with Pulse Frequency
There are 20 known major drug interactions with Transderm Scop.
Common Transderm Scop Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Major
The risk or severity of adverse effects can be increased when Scopolamine is combined with Aclidinium.
Azelastine
Major
Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Cimetropium
Major
The risk or severity of adverse effects can be increased when Scopolamine is combined with Cimetropium.
Deutetrabenazine
Major
The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.
Eluxadoline
Major
The risk or severity of constipation can be increased when Scopolamine is combined with Eluxadoline.
Transderm Scop Toxicity & Overdose Risk
Overdosing on scopolamine can lead to symptoms such as drowsiness, confusion, agitation, hallucinations, seizures, dry skin and mouth, increased heart rate, high blood pressure, and abnormal heart rhythms. If a person has swallowed a patch, it may need to be removed or activated charcoal administered. In animals, the toxic dose has been found to be 1880 mg/kg in mice and 1270 mg/kg in rats when taken by mouth, and 1650 mg/kg in mice and 296 mg/kg in rats when taken through the skin.
Transderm Scop Novel Uses: Which Conditions Have a Clinical Trial Featuring Transderm Scop?
A total of 4 active studies are currently investigating the potential of Transderm Scop in providing relief from Motion Sickness, Nausea and Airsickness.
Condition
Clinical Trials
Trial Phases
Motion Sickness
0 Actively Recruiting
Nausea
5 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable
Airsickness
2 Actively Recruiting
Not Applicable, Phase 3
Nausea
0 Actively Recruiting
Anesthetic premedication therapy
0 Actively Recruiting
Transderm Scop Reviews: What are patients saying about Transderm Scop?
5
Patient Review
4/15/2021
Transderm Scop for Motion Sickness
5
Patient Review
2/16/2018
Transderm Scop for Motion Sickness
5
Patient Review
6/9/2022
Transderm Scop for Prevention of Motion Sickness
5
Patient Review
3/3/2017
Transderm Scop for Prevention of Motion Sickness
5
Patient Review
2/5/2017
Transderm Scop for Motion Sickness
4.7
Patient Review
10/20/2015
Transderm Scop for Motion Sickness
4.3
Patient Review
8/6/2015
Transderm Scop for Motion Sickness
3.3
Patient Review
5/19/2019
Transderm Scop for Motion Sickness
3
Patient Review
2/19/2020
Transderm Scop for Motion Sickness
2.7
Patient Review
8/20/2015
Transderm Scop for Motion Sickness
2.3
Patient Review
11/4/2019
Transderm Scop for Prevention of Motion Sickness
1
Patient Review
6/15/2016
Transderm Scop for Prevent Nausea and Vomiting After Surgery
Patient Q&A Section about transderm scop
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Transderm Scop over the counter?
"The drug Scopolamine (Transderm Scop) is not able to be bought over the counter and requires a prescription from a medical provider. This is because it can have severe side effects if the person taking it has other medical conditions or is taking other medications."
Answered by AI
When do you apply Transderm Scop?
"If you are prone to motion sickness, it is recommended that you apply a Transderm Scop patch to a hairless area behind your ear at least four hours before the activity. If you need the treatment for more than three days, remove the patch from behind your ear."
Answered by AI
Is Transderm Scop still available?
"Perrigo has discontinued scopolamine transdermal system due to business reasons. The discontinuation is not due to product quality, safety, or efficacy concerns. Scopolamine transdermal system has been listed on the FDA Drug Shortage site. After researching the issue further, Perrigo has confirmed that the product has been discontinued."
Answered by AI
What is Transderm Scop used for?
"Scopolamine is used to stop nausea and vomiting that is caused by motion sickness or medicine used during surgery. Scopolamine is a type of medicine called an antimuscarinic. Scopolamine works by blocking the effects of a natural substance called acetylcholine on the central nervous system."
Answered by AI